I'll research IDEX Corporation (IEX) to build a well-grounded earnings preview. Let me start gathering information.Let me read the most recent Q1 2026 earnings materials and get recent news.Let me get recent news and the year-ago Q2 2025 comparison figures.Let me check for any recent news/press releases in the second quarter of 2026 (acquisitions, etc.).I have what I need. Let me verify a couple of derived figures before writing.Here is the earnings preview.
IDEX heads into Q2 with the best momentum it has shown in two years, a record order book, and a stock that has already priced in a lot of good news. The debate is no longer whether the "advantaged markets" strategy is working in HST — it clearly is — but whether the short-cycle industrial businesses (FMT/FSDP) are finally inflecting, and whether that's enough to justify a stock trading near all-time highs at ~26.6x this year's EPS.
Management guided Q2 2026 specifically on the Q1 call:
| Metric | Q2 2026 Guide | Q2 2025 Actual | Implied YoY |
|---|---|---|---|
| Organic sales growth | +3% to +4% | +1% | Accelerating |
| Adjusted EBITDA margin | 26.5%–27.0% | 27.4% | Down ~40–90 bps |
| Adjusted diluted EPS | $2.07–$2.12 | $2.07 | Flat to +2.4% |
Two things to keep in mind on the optics: - The EPS comp looks unimpressive by design. Q2 2025 was actually a relatively strong-margin quarter (27.4% EBITDA, adj. EPS $2.07) before the company cut its full-year guide that same morning. So a $2.07–$2.12 guide is essentially flat-to-up against a tough margin comp, even though the full year is guided to mid-to-high single-digit EPS growth ($8.35–$8.55). That means the back half carries the growth — watch whether the Q2 print and commentary support that H2 acceleration. - Margin down YoY is expected, not a red flag. It's driven by mix (fast-growing acquired HST businesses like Mott, Muon, Micro-LAM run below segment margins) and FMT/FSDP volume deleverage — not pricing or cost problems.
1. Orders are at record levels and HST backlog keeps building. Q1 delivered record orders of $988M, +13% reported / +10% organic, led by HST organic orders of +17%. This is unusual for IDEX, which historically had limited visibility (they typically enter a quarter ~50% booked). HST's backlog build now gives real visibility "into 2027," anchored to secular demand in data center power, semiconductors, optical switching, and space & defense.
2. The full-year guide was already raised once. After Q1, management lifted organic growth from 1–2% to 3–4% and EPS by $0.20 to $8.35–$8.55. Notably, management said the raise was driven by internal growth initiatives and M&A, not a bet on a cyclical rebound — so there's a conservative cushion baked in if short-cycle markets improve.
3. Short-cycle green shoots. FMT orders grew +9% organic in Q1, led by the water platform (municipal/stormwater plus a high-purity semiconductor water business that flipped from headwind to tailwind) and mining. Management described an improving monthly cadence (weak January → stronger March → holding in April) but stopped short of calling a clean inflection, citing chemical/general-industrial softness and geopolitical uncertainty.
HST order/backlog durability. Does the backlog build continue, or was Q1's +17% orders a peak? The bull case on the stock rests on HST sustaining high-single/double-digit growth with a multi-year runway. Any deceleration in the AI/data-center/space-defense order signal is the single most important risk to the thesis.
HST incremental margins. Flow-through has been stuck in the low-to-mid 30s vs. a historical target near 40%. Management expects "mid-30s" for the year, with the path to 40% dependent on (a) 8020 pruning to lift margins at acquired businesses and (b) a life sciences recovery. Progress here matters more than the headline margin.
FMT/FSDP — real inflection or head-fake? FMT organic sales were only +2% despite +9% orders (a lot burns off within the quarter, and some Q1 mining/pumps demand was likely pulled forward). Look for whether the short-cycle diagnostic businesses start moving together — Ashleman's stated signal for a genuine cyclical turn.
Life sciences. Still pressured by China and NIH/academic funding; core fluidics and optical filters growing only low-single-digit. It's a high-margin business, so any inflection is a margin and growth tailwind. Watch for signs it's bottoming.
Another guidance raise + capital deployment. With a Q1 beat and cushion in the guide, the market will look for a second FY raise. On capital: expect the ~$76M/quarter buyback pace to continue, gross leverage ~2x, ~$1.1B liquidity, and an active bolt-on M&A pipeline. Also watch for updates on tariffs (management sees roughly net-neutral impact) and any IEEPA refund developments.
Reaction risk is high and asymmetric. IDEX has moved sharply on recent prints: -11% on the Q2 2025 guide cut, but +6% after Q1 2026 and +5% after Q4 2025. Given the run into the quarter and premium multiple, the bar is high: a Q1-style beat-and-raise is arguably needed to sustain the stock, while any hint that HST orders are cooling or that FMT/FSDP's inflection is stalling could prompt an outsized pullback.
The fundamental trajectory is the strongest it's been in two years — record orders, rising HST visibility into 2027, and an already-raised guide with conservatism embedded. The setup into Q2 is fundamentally favorable but priced for continued execution. The key swing factors are (1) HST order/backlog durability and margin flow-through, and (2) confirmation that short-cycle FMT/FSDP is genuinely inflecting rather than just stabilizing. Deliver both, plus a second guide raise, and the premium multiple holds; disappoint on either, and the risk/reward skews to the downside given the recent run.
Preview based on IDEX's Q1 2026 results/call (Apr 29, 2026), Q2 2025 results (Jul 30, 2025), and share-price history through Jul 28, 2026. Figures are non-GAAP where noted (adjusted EPS/EBITDA). This is research/analysis, not investment advice.